Nantong, Jiangsu Province, China
Merck broke ground in August of 2014 on a $108 million pharmaceutical manufacturing plant in Nantong, China. Located in the BioSpark development, the 430,560-sf facility will produce therapeutics for the treatment of cardiovascular diseases, thyroid disorders, and diabetes. The highly efficient project is designed to minimize waste during the manufacturing process. Completion is expected in 2016 with commercial operations commencing in 2017.
Source
